Alice E Taylor

US Patent:

7932212, Apr 26, 2011

Filed:

Nov 17, 2009

Appl. No.:

12/620013

Inventors:

Alice P. Taylor - Alpharetta GA, US
David M. Goldenberg - Mendham NJ, US
Chien-Hsing Chang - Downingtown PA, US

Assignee:

Center for Molecular Medicine & Immunology - Belleville NJ
Immunomedics, Inc. - Morris Plains NJ

International Classification:

C40B 30/04

US Classification:

506 9

Abstract:

The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.

US Patent:

20110189268, Aug 4, 2011

Filed:

Mar 11, 2011

Appl. No.:

13/046205

Inventors:

Alice P. Taylor - Alpharetta GA, US
David M. Goldenberg - Mendham NJ, US
Chien-Hsing Chang - Downingtown PA, US

Assignee:

CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY - Belleville NJ
IMMUNOMEDICS, INC. - Morris Plains NJ

International Classification:

A61K 9/127
C07K 2/00
C07K 7/08
C07K 7/06
A61K 38/02
C12N 9/96
C07K 19/00
A61K 38/14
A61P 35/00
A61P 35/02
A61P 37/02
B82Y 5/00

US Classification:

424450, 530300, 530326, 530328, 530327, 514 11, 435188, 5303917, 514 209, 530350, 530399, 977773, 977915

Abstract:

The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.